Industry news that matters to you.  Learn more

Archives for July 2011

Advion BioServices First to Offer SISCAPA Assay Services for Biomarker Assays

Advion BioServices, a subsidiary of Advion BioSciences, Inc. and a leading bioanalytical contract research organization, will immediately begin offering its clients SISCAPA LC/MS Biomarker assay services. This is made possible by a license and collaboration agreement Advion BioServices has executed with SISCAPA Assay Technologies, Inc. of Rockville, MD.

NextGen Sciences Launches Multiplex Protein CSF Biomarker Assay for Multiple Sclerosis

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its csfmultiplesclerosis25 multiplex protein assay for multiple sclerosis. The assay simultaneously measures 25 human CSF (cerebrospinal fluid) proteins that are believed to have potential as biomarkers for the disease.

MD Anderson Cancer Center Acquires Second Aushon 2470 Microarray Printer for its RPPA Core Facility

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis announced today that the Department of Systems Biology at the MD Anderson Cancer Center has acquired another 2470 microarray printer from Aushon BioSystems. The new 2470 Arrayer will be utilized in the Cancer Center Support Grant (CCSG) Functional Proteomics Reverse Phase Protein Array (RPPA) Facility, a core facility that serves all researchers at MD Anderson Cancer Center, as well as other academic institutions and industries. Extremely high demand for RPPA data and the proven performance of the existing 2470 Arrayer helped drive the acquisition of the additional microarray printer. Combined with the current 2470 on-site, the ability of the Functional Proteomics RPPA Facility to meet the higher throughput demands for biomarker research and diagnostic testing on cancer patients’ protein pathways and drug reaction will be significantly expanded.

HYCOR Broadens Diagnostic Offerings, Announces Agreements to License Biomarkers for Celiac Disease and Rheumatoid Arthritis

HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products, today announced that it has signed an agreement with Eurospital — a manufacturer of pharmaceutical products, medical-surgical and diagnostic devices — to license its tTG biomarker in all countries covered by the patent (excluding the US and Canada) for its ability to diagnose celiac disease. HYCOR today also announced that it has signed an agreement with AXIS-SHIELD — a developer of in vitro diagnostic tests — to license its anti-CCP biomarker for its ability to diagnose rheumatoid arthritis (RA). Customers will have access to these critical biomarkers from HYCOR in the coming weeks.

Skyline Diagnostics establishes Research Collaboration with Janssen

Skyline Diagnostics B.V. (Skyline), a biotechnology company focusing on development and marketing of gene signature-based diagnostic assays based in The Netherlands, today announced that it has signed a Research Agreement with Johnson & Johnson Pharmaceutical Research and Development division of Janssen Pharmaceutica N.V. (Janssen).